| scholarly article | Q13442814 |
| P50 | author | Ton J Rabelink | Q40341003 |
| P2093 | author name string | Eelco J P de Koning | |
| Manuel Castro Cabezas | |||
| Jeroen P H van Wijk | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fatty acid | Q61476 |
| triglyceride | Q186319 | ||
| (RS)-rosiglitazone | Q424771 | ||
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 844-849 | |
| P577 | publication date | 2005-04-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes | |
| P478 | volume | 28 |
| Q89586580 | Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study |
| Q38305514 | Acute and selective regulation of glyceroneogenesis and cytosolic phosphoenolpyruvate carboxykinase in adipose tissue by thiazolidinediones in type 2 diabetes. |
| Q51352222 | Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. |
| Q46024732 | Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. |
| Q51468997 | Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. |
| Q42832603 | Effect of pioglitazone on visfatin expression in 3T3-L1 adipocytes and SD rats |
| Q51381989 | Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. |
| Q37875220 | Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes |
| Q37240102 | Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes |
| Q51472462 | Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease. |
| Q37892758 | Gut-liver interaction in triglyceride-rich lipoprotein metabolism |
| Q36562259 | Impact of thiazolidenediones on serum lipoprotein levels |
| Q36232378 | Impact of thiazolidinedione therapy on atherogenesis |
| Q46973485 | Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARalpha/gamma agonist, tesaglitazar |
| Q42363125 | Is it time to break the fast?-a paradigm shift in clinical lipidology |
| Q40793611 | PPARs in Regulation of Paraoxonases: Control of Oxidative Stress and Inflammation Pathways |
| Q42988793 | Peroxisome proliferator activated receptors and lipoprotein metabolism |
| Q38110890 | Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis. |
| Q46905943 | The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. |
| Q34503392 | Unsaturated FAs prevent palmitate-induced LOX-1 induction via inhibition of ER stress in macrophages |
| Q51495360 | Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. |
Search more.